Among patients with EGFR-positive NSQ cancer, subtypes were exon-19 deletion (2999 patients [43.7%]), exon-21 L858R substitution (2591 patients [37.7%]), T790M (556 patients [8.1%]), exon-20 insertion (185 patients [2.7%]), and other EGFR variants (535 patients [7.8%]) (Figure 1C). This evidence concerns the gene EGFR and cancer.